First drug approved in 2021

Poxel is developing a pipeline of several mid-to-late-stage drug candidates targeting the mitochondrial dysfunction. Imeglimin was approved as TWYMEEG® for type 2 diabetes in Japan in June 2021 and was launched in September 2021. Imeglimin has also successfully completed Phase 2 development in the U.S. and EU. PXL770 and PXL065 are in mid-stage development for NASH. We are also evaluating our AMPK activation and TZD platforms for other chronic and rare metabolic diseases with the objective to launch Phase 2a proof-of-concept studies in ALD mid-2022.

VIEW OUR CANDIDATES

Latest News

Poxel Announces Positive Histology Results from Phase 2 NASH Trial (DESTINY-1) for PXL065, a Novel, Proprietary Deuterium-Stabilized R-stereoisomer of Pioglitazone

PXL065 Phase 2 trial for the treatment of NASH met its primary efficacy endpoint for liver fat content reduction at 36-weeks for all doses. Histology findings from paired liver biopsies showed strong improvement in…

Read this Press Release: Poxel Announces Positive Histology Results from Phase 2 NASH Trial (DESTINY-1) for PXL065, a Novel, Proprietary Deuterium-Stabilized R-stereoisomer of Pioglitazone

Poxel Reports Financial Results for First Half 2022 and Provides a Corporate Update

Positive results from Phase 2 NASH Trial (DESTINY-1) for PXL065 reported: Primary efficacy endpoint met: PXL065-treated patients achieved statistically significant improvements in the relative decrease in liver fat…

Read this Press Release: Poxel Reports Financial Results for First Half 2022 and Provides a Corporate Update

Poxel Announces Positive Results from Phase 2 NASH Trial (DESTINY-1) for PXL065, A Novel, Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone

The Phase 2 trial for the treatment of NASH met its primary efficacy endpoint; PXL065-treated patients achieved statistically significant improvements in the relative decrease in liver fat content measured by…

Read this Press Release: Poxel Announces Positive Results from Phase 2 NASH Trial (DESTINY-1) for PXL065, A Novel, Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone
Click here to show the previous slide Click here to show the next slide

Upcoming Events

5th European Workshop on AMPK and AMPK-related kinases

H.C. Wainwright 6th Annual NASH Conference

ALD Connect 2022 Annual Meeting & Patient Learning Academy

Jefferies Healthcare Conference

Click here to show the previous slide Click here to show the next slide

Innovative Pipeline of First-In-Class Products

Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for NASH and rare metabolic diseases.

View Pipeline
Innovative Pipeline of First-In-Class Products

Targeting Mitochondrial Dysfunction

Imeglimin was approved as TWYMEEG® for type 2 diabetes in Japan in June 2021 and will be marketed by our strategic partner, Sumitomo Dainippon Pharma, in 2021. Imeglimin has successfully completed Phase 2 development in the U.S. and EU. PXL770 and PXL065 are in mid-stage development for NASH. We are also evaluating our AMPK activation and TZD platforms for other chronic and rare metabolic diseases.

View Our Candidates
Targeting Mitochondrial Dysfunction

Backed by Strong Leadership

Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.

Meet Our Team
Backed by Strong Leadership